The clinical pharmacologic profile of reboxetine: Does it involve the putative neurobiological substrates of wellbeing?

Journal of Affective Disorders

Volumn 51, Issue 3, 1998, Pages 313-322

  Healy, David ^a   Healy, Helen ^b  

^a Hergest Unit   (United Kingdom)

^b BANGOR UNIVERSITY   (United Kingdom)

Author keywords

Antidepressant; Monoamine theories; Quality of life; Reboxetine; Temperament

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; REBOXETINE;

ARTICLE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SWEATING; WELLBEING;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER; HUMANS; MIDDLE AGED; MORPHOLINES; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES; SOCIAL ADJUSTMENT; TEMPERAMENT; TREATMENT OUTCOME;

EID: 0032415672     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(98)00227-4     Document Type: Article

References (56)

1. Akiskal, H.S., 1995. Toward a temperament-based approach to depression: implications for neurobiologic research. Adv. Biochem. Pharmacol. 49, 99-112.
2. Akiskal, H.S., 1996. The temperamental foundations of affective disorders. in: Munct, C. et al. (Ed.), Interpersonal Factors in the Origin and Course of Affective Disorders, London Gaskell, pp. 3-30.
3. Akiskal, H.S., 1997. Toward an innovative classification of depression: temperament and pharmacological response. Drugs Today 33, 183-190.
4. Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, American Psychiatric Association, Washington D.C.
5. Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, American Psychiatric Association, Washington D.C.
6. Artigas, F., Perez, V., Alvarez, E., 1994. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 51, 248-251.
7. Aston-Jones, G., Akaoka, H., Charlety, P., Chouvet, G., 1991. Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurones. J. Neurosci. 11, 760-769.
8. Baldwin, D., Hawley, C., Szabi, E., 1998. Reboxetine in the treatment of depression: early clinical experience in the UK. Internat. J. Psychiatry Clin. Pract. 2, 195-201.
9. Ban, T.A., Gaszner, P., Aguglia, E., Batista, R., Castillo, A., Lipcsey, A., Macher, J.P., Torres-Ruiz, A., Vergara, L., 1998. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Human Psychopharm. 13, S29-S39.
10. Berzewski, H., Van Moffaert, M., Gagiano, C.A., 1997. Efficacy arid tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur. Neuropsychopharmacol. 7, S37-S47.
11. Bosc, M., Dubini, A., Polin, V., 1997. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur. Neuropsychopharmacol. 7, S57-S70.
12. Breier, A., Kestler, L., Adler, C., Elman, I., Wiesenfeld, N., Malhotra, A., Pickar, D., 1998. Dopamine D-2 receptor density and personal detachment in healthy subjects. Am. J. Psychiatry 155, 1440-1442.
13. Brunello, N., Racagni, G., 1998. Rationale for the development of noradrenaline reuptake inhibitors. Human Psychopharmacol. 13, S13-S19.
14. Bunney, W.E., Davis, J.M., 1965. Norepinephrine in depressive reactions. Arch. Gen. Psychiatry 13, 483-494.
15. Carlsson, A., 1996. The rise of neuropsychopharmacology: impact on basic and clinical neuroscience. in: Healy, D. (Ed.), The Psychopharmacologists, Chapman and Hall, London, pp. 51-80.
16. Carlsson, A., Corrodi, H., Fuxe, K., Hokfelt, T., 1969. Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine. Eur. J. Pharmacol. 5, 357-366.
17. Coppen, A., 1967. The biochemistry of affective disorders. Brit. J. Psychiatry 113, 1237-1264.
18. Coppen, A., 1972. Indoleamines and affective disorders. J. Psychiatr. Res. 9, 163-171.
19. Delgado, P.L., Price, L.H., Miller, H.L., Salomon, R.M., Licinio, J., Krystal, J.H., Heninger, G.R., Charney, D.S., 1991. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol. Bull. 27, 321-330.
20. Delgado, PL., Miller, H.L., Salomon, R.M., Licinio, J., Heninger, G.R., Gelenberg, A.J., Charney, D.S., 1993. Monoamines and the mechanism of antidepressant action effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol. Bull. 29, 389-396.
21. Dostert, P., Benedetti, M.S., Poggesi, I., 1997. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur. Neuropsychopharmacol. 7, S23-S35.
22. Dubini, A., Bosc, M., Polin, V., 1997. Do noradrenaline and serotonin differentially affect social motivation and behavior? Eur. Neuropsychopharmacol. 7, S49-S56.
23. Farde, L., Gustavsson, J.P., Jonsson, E., 1997. D2 dopamine receptors and personality traits. Nature 380, 590.
24. Gantt, W.H., 1967. Role of drugs in conditioning. neuropsychopharmacology. in: Brill, H., Cole, J.O., Deniker, P., Hippiis, H., Bradely, P.B. (Eds.), Proceedings of the Fifth International Congress of the CINP, Excerpta Medica, Amsterdam, pp. 811-814.
25. Goodnick, P.J., Goldstein, B.J., 1998. SSRIs in affective disorders: efficacy and quality of life. J. Psychopharmacol. 12, S21-S53.
26. Guy, V.I., 1976. Clinical global impressions, in: ECDEU Assessment Manual For Psychopharmacology, US Dept of Health, Education and Welfare, Rockville, pp. 217-222.
27. Hamilton, M., 1960. A rating scale for depression. J. Neurosurg. Psych. 23, 56-62.
28. Healy, D., McMonagle, T., 1997. The enhancement of social functioning as a therapeutic principle in the management of depression. J. Psychopharmacol. 11 (4), S25-S31.
29. Healy, D., 1997. The Antidepressant Era, Harvard University Press, Cambridge Mass.
30. Healy, D., 1998a. Reboxetine, fluoxetine and social functioning as an outcome measure in antidepressant trails: implications. Primary Care Psychiatry 4, 81-89.
31. Healy, D., 1998b. Meta-analysis of trials comparing antidepressants with active placebos: commentary. Br. J. Psychiatry 172, 232-234.
32. Joyce, P.R., Mulder, R.T., Cloninger, C.R., 1994. Temperament predicts clomipramine and desipramine response in major depression. J. Affect. Disord. 30, 35-46.
33. Kielholz, P., 1968. Die Behandlung endogener Depressionem mit Psych pharmaka. Deutsch Med Wochenschrft 93, 701-710.
34. Knutson et al., 1998. Please supply reference.
35. Leonard, B.E., Healy, D., 1998. The Differential Effects of Antidepressants, Martin Dunitz & Co, London.
36. Lonnquist, J., Sintonen, H., Syvalahti, E., Appelberg, B., Koskinen, T., Mannikko, T., Mehtonen, O.-P., Naarala, M., Sihvo, S., Auvinen, J., Pitkanen, H., 1994. Antidepressant efficacy and quality of life in depression: a double..blind study with moclobemide and fluoxetine. Acta Psychiatr. Scand. 89, 363-369.
37. Maas, J., Koslow, J., Katz, M., Bowden, C., Gibbons, R., Stokes, P., Robins, E., Davis, J.M., 1984. Pine-treatment neurotransmitter levels and response to tricyclic antidepressant drugs. Am. J. Psychiatry 141, 1159-1171.
38. Manier, D.H., Gillespie, D.D., Steranka, L.R., Sulser, F., 1984. A pivotal role for serotonin (5-HT) in the regulation of beta adrenoceptors by antidepressants: Reversibility of the action parachlorophylalanine by 5-hydroxytroptophan. Experientia 40, 1223-1226.
39. Massana, J., Moller, H.-J., Burrows, D., Montenegro, R.M., in press. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorders. Int. Clin. Psychopharmacol.
40. Melloni, P., Carniel, G., Delia Toree, A., Bonsignori, A., Buonamici, M., Pozzi, O., Raccardi, S., Rossi, A.C., 1984. Potential antidepressant agents a-Aryloxybenzl derivatives of ethanolamine and morpholine. Eur. J. Med. Chem. Chim. Ther. 19, 235-242.
41. Montgomery, S., Asberg, M., 1979. A new depression rating scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389.
42. Montgomery, S., 1997. Is there a role for a pure noradrenergic drug in the treatment of depression? Eur. Neuropsychopharmacol. 7, S3-S9.
43. Mucci, M., 1997. Reboxetine: a review of antidepressant tolerability. J. Psychopharmacol. 11 (4), S33-S37.
44. Nelson, J.C., Mazure, C., Quinlan, D.M., Jatlow, P., 1984. Drug responsive symptoms in melancholia. Arch. Gen. Psychiatry 41, 663-668.
45. Nelson, J.C., Mazure, C., 1990. A rating scale specific for tricyclic response in melancholia: the TRIM. J. Clin. Psychopharmacol. 10, 252-260.
46. Schildkraut, J.J., 1965. The catecholamine hypothesis of affective disorders. A review of supporting evidence. Am. J. Psychiatry 122, 509-522.
47. Souetre, E., Martin, P., Lozet, H., Monteban, H., 1996. Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants. Int. Clin. Psychopharmacol. 11, 45-52.
48. Stassen, H., Angst, J., Delini-Stula, A., 1997. Delayed onset of action of antidepressant drugs. Eur. Psychiatry 12, 166-176.
49. Svensson, T., 1997. Electrophysiology of brain noradrenaline neurons and the mode of action of antidepressant drugs. in: Briley, M., Montgomery, S. (Eds.), Antidepressant Therapy at the Dawn of the Third Millenium, Martin Dunitz, London, pp. 19-35.
50. Szabadi, E., Bradshaw, C.M., Boston, P.F., Langley, R.W., 1998. The human pharmacology of reboxetine. Human Psychopharmacol. 13, S3-S12.
51. Thunedborg, K., Black, C.H., Bech, P., 1995. Beyond the Hamilton Depression Scores in Long-Term Treatment of Manic-Melancholic Patients: Prediction of Recurrence of Depression by Quality of Life Measurements. Psychother. Psychosom. 64, 131-140.
52. Vetulani, J., Stawarz, R., Pingell, J., Sulser, F., 1996. A possible common mechanism of action of antidepressant drug treatments. NS Arch. Pharmacol. 243, 109-114.
53. Weissman, M.M., 1997. Beyond symptoms: social functioning and the new antidepressants. J. Psychopharmacol. 11 (4), S5-S8.
54. Weissman, M.M., Klerman, G.L., Paykel, E.S., Prusoff, B., Hanson, B., 1974. Treatment effects on the social adjustment of depressed patients. Arch. Gen. Psychiatry 30, 771-778.
55. Wells, K.B., Stewart, A., Hays, R., Buinnam, A., Rogers, W., Daniels, M., Berry, S., Greenfield, S., Ware, J., 1989. The functioning and wellbeing of depressed patients: results from the medical outcomes study. J. Am. Med. Assoc. 262, 914-919.
56. Wells, K.B., Buinnam, M.A., Rogers, W., Hays, R., Camp, P., 1992. The course of depression in adult outpatients: Results from the medical outcomes study. Arch Gen. Psychiatry 49, 788-794.